Equities Analysts Set Expectations for PCRX Q3 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX) – HC Wainwright cut their Q3 2026 earnings per share estimates for Pacira BioSciences in a report issued on Wednesday, August 5th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $0.47 per share for the quarter, down from their previous forecast of $0.48. HC Wainwright currently has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Pacira BioSciences’ current full-year earnings is $1.94 per share. HC Wainwright also issued estimates for Pacira BioSciences’ FY2026 earnings at $1.88 EPS, Q1 2027 earnings at $0.38 EPS, Q2 2027 earnings at $0.31 EPS, Q3 2027 earnings at $0.64 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $1.99 EPS.

Other equities research analysts have also recently issued reports about the company. Royal Bank Of Canada upped their price target on Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a research report on Wednesday, August 5th. Needham & Company LLC raised their price objective on shares of Pacira BioSciences from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Weiss Ratings raised shares of Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, May 20th. Three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Pacira BioSciences presently has a consensus rating of “Hold” and a consensus price target of $29.80.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $24.38 on Wednesday. Pacira BioSciences has a 52-week low of $18.80 and a 52-week high of $27.66. The stock’s 50-day simple moving average is $24.76 and its 200 day simple moving average is $23.50. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04. The stock has a market capitalization of $971.79 million, a price-to-earnings ratio of 69.66 and a beta of 0.27.

Pacira BioSciences (NASDAQ:PCRX) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.08. Pacira BioSciences had a return on equity of 9.68% and a net margin of 1.96%.The company had revenue of $192.40 million during the quarter, compared to analysts’ expectations of $191.06 million. During the same period in the previous year, the business earned $0.74 earnings per share. The firm’s quarterly revenue was up 6.2% compared to the same quarter last year.

Insider Activity

In other news, SVP Lauren Riker sold 6,115 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the transaction, the senior vice president owned 62,284 shares of the company’s stock, valued at approximately $1,463,674. The trade was a 8.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Pacira BioSciences

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Impax Asset Management Group plc lifted its holdings in shares of Pacira BioSciences by 25.0% during the 4th quarter. Impax Asset Management Group plc now owns 750,027 shares of the company’s stock worth $19,411,000 after acquiring an additional 150,000 shares during the last quarter. Hillsdale Investment Management Inc. bought a new position in Pacira BioSciences in the fourth quarter valued at $7,976,000. LSV Asset Management increased its stake in Pacira BioSciences by 179.8% in the fourth quarter. LSV Asset Management now owns 319,800 shares of the company’s stock valued at $8,276,000 after acquiring an additional 205,500 shares during the last quarter. Gagnon Advisors LLC raised its position in Pacira BioSciences by 22.3% during the fourth quarter. Gagnon Advisors LLC now owns 260,908 shares of the company’s stock valued at $6,752,000 after purchasing an additional 47,506 shares in the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH raised its position in Pacira BioSciences by 360.1% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 69,097 shares of the company’s stock valued at $1,788,000 after purchasing an additional 54,079 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Key Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $1.88 from $1.73 and increased its Q4 2026 estimate to $0.68 from $0.64. These revisions suggest improved near-term earnings expectations for Pacira BioSciences.
• Positive Sentiment: The firm continues to project earnings growth into 2027, including estimates of $0.38 EPS for Q1, $0.31 for Q2, $0.64 for Q3 and $0.66 for Q4. Its $38 price target implies substantial potential upside if those forecasts are achieved.
• Positive Sentiment: A recent article examines whether Pacira is reframing its non-opioid pain-management strategy around PCRX-201 gene therapy, potentially highlighting a longer-term growth opportunity beyond its existing products. Is Pacira BioSciences Quietly Reframing Its Non-Opioid Strategy Around PCRX-201 Gene Therapy?
• Neutral Sentiment: HC Wainwright’s estimates for Q1–Q4 2027 imply FY2027 EPS of $1.99, compared with the current consensus estimate of $1.94, while its Buy rating remains unchanged.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS estimate slightly to $0.47 from $0.48 and cut its FY2027 forecast to $1.99 from $2.29. The sizable long-term reduction may weigh on sentiment despite the higher FY2026 outlook.
• Neutral Sentiment: Reported short interest was listed at zero shares with a zero-day days-to-cover ratio. Because the figures appear inconsistent with normal market data, they provide little useful signal for PCRX investors.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.